Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018

NCT03582826
ClinicalTrials.gov
MEBO Gut Microbiome Study
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 85/100
3 kits per person

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact map@meboresearch.org
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
BannerFans.com
RESEARCH DETAILS

DONATIONS THRU 31-NOV-2016:
£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14

MEBO UK PAYPAL FOR TRINZYME

********
MEBO US PAYPAL FOR TRINZYME

Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Tuesday, March 29, 2011

MEBO-Eliapharma TMAU Testing Update and next batch of tests

Even as we wait for the results of the 38 specimen of the 1st batch analyzed by Eliapharma, we already have an additional 12 samples for the next batch.
At this time, Eliapharma is writing the reports of the first 38 samples received for TMAU Testing for Primary TMAU, Secondary TMAU, or negative results.

Urine Creatinine Test: In addition to TMAU testing, Eliapharma is analyzing each sample to measure urine creatinine concentration levels to act as the reference point for measuring TMA and TMAO. This is something also done by Nigel Manning in the UK, as noted in his paper, TMAU - diagnostic testing at Sheffield Children's Hospital, which Nigel wrote for MEBO's Meetup in Nashville 2010.

A urine creatinine concentration level test can be done on its own or with other tests that determine the relative amounts of other substances being excreted in the urine. High creatinine levels indicate a pure test, whereas low amounts of creatinine in the urine indicate an altered test perhaps by drinking excessive amounts of water or taking medication containing diuretics. This additional measure to test the creatinine concentration in each specimen serves to ensure that the urine samples are of good quality. Normally, this test is done as a screening test to evaluate kidney function, but also to provide information on other chemicals in the urine such as albumin or protein.


Even as we wait for the results of the 38 specimen of the 1st batch analyzed by Eliapharma, we already have an additional 12 samples for the next batch. In addition, so far 5 people have expressed interest in providing a sample during the Washington DC Meetup on the weekend of the 9th and 10th of April, and others might decide to do the test as well once they’re at the meetup. So, by mid April, we should have close to 20 samples, and hopefully complete the 30 required to run the test by early May. As per our agreement with Eliapharma, the lab will analyze approximately 30 samples at a time.


If you would like to test in our MEBO International TMAU Testing Program, please fill the test following, MEBO-Eliapharma TMAU Test Requisition/Survey Form.

We are looking forward to receiving the results of this first batch of 38 samples sometime this week.

María

María de la Torre
President and Executive Director



0 comments:

Post a Comment